# ${\bf (19) \ World \ Intellectual \ Property \ Organization}$

International Bureau



# ) | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1881 | 1

(43) International Publication Date 23 March 2006 (23.03.2006)

**PCT** 

# (10) International Publication Number WO 2006/032009 A3

(51) International Patent Classification:

 C12Q 1/00 (2006.01)
 G01N 33/48 (2006.01)

 C12Q 1/68 (2006.01)
 G01N 33/53 (2006.01)

 G01N 21/00 (2006.01)
 G01N 33/567 (2006.01)

 G01N 33/00 (2006.01)
 G01N 33/574 (2006.01)

(21) International Application Number:

PCT/US2005/033095

(22) International Filing Date:

14 September 2005 (14.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/609,936 14 September 2004 (14.09.2004) US

(71) Applicant (for all designated States except US): BAYER PHARMACEUTICALS CORPORATION [US/US]; 400 Morgan Lane, West Haven, CT 06516 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BIGWOOD, Douglas [US/US]; 72 Kelsey Springs Drive, Madison, CT 06443 (US).

(74) Agents: GREENMAN, Jeffrey, M. et al.; Bayer Pharmaceuticals Corporation, 400 Morgan Lane, West Haven, CT 06516 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 8 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING CANCER THERAPY

(57) Abstract: The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of cortactin as a biomarker for kinase inhibitors.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/33095

A. CLASSIFICATION OF SUBJECT MATTER  IPC: C12Q 1/00( 2006.01),1/68( 2006.01);G01N 21/00( 2006.01),21/75( 2006.01),33/00( 2006.01),33/48( 2006.01),33/53( 2006.01),33/567( 2006.01),33/574( 2006.01)				
USPC: 435/4,6,7.1,7.21,7.23;436/63,64,86,174,164 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELI	OS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/4, 6, 7.1, 7.21, 7.23; 436/63, 64, 86, 174, 164				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) GenCore databases; WEST				
C. DOCI	JMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.	
A	SCHUURING, ED et al. The produce of the EMS1		1-25	
Y	human carcinomas, is homologous to a v-src substra contact sites. Molecular And Cellular Biology. Ma and attached database sheets.		26-33	
A	MIGLARESE, M.R. et al. The protein tyrosine sub-		1-25	
 Ү	expressed in murine B lymphoid tumors. Oncogene. attached database sheets.	1994, Vol. 9, pages 1989-1997 and	26-33	
		,		
		·		
	·			
		·		
Further documents are listed in the continuation of Box C. See patent family annex.				
-	pecial categories of cited documents:	"T" later document published after the inter date and not in conflict with the applica	tion but cited to understand the	
"A" document particular	defining the general state of the art which is not considered to be of relevance	principle or theory underlying the inven	ition	
"B" earlier application or patent published on or after the international filing date		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being		
"O" document referring to an oral disclosure, use, exhibition or other means		obvious to a person skilled in the art	, such combination demg	
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family		
Date of the ac	ctual completion of the international search	Date of mailing of the international scarce	h report	
30 May 2006			<del>2</del> <del>(</del>	
	illing address of the ISA/US I Stop PCT, Atm: ISA/US	Authorized officer SAWQO L		
Con	missioner for Patents	Aldna M. Harris, Ph.D.		
	Box 1450 tandria, Virginia 22313-1450	Telephone No. 571-272-1600	0	
	. (571) 273-3201			

Form PCT/ISA/210 (second sheet) (April 2005)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/33095

	Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)			
on paper in electronic form  c. time of filing/furnishing contained in the international application as filed filed together with the international application in electronic form furnished subsequently to this Authority for the purposes of search  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has be filed or furnished, the required statements that the information in the subsequent or additional copies is identical to the in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	invent	tion, the international search was carried out on the basis of:  type of material  a sequence listing		
contained in the international application as filed  filed together with the international application in electronic form  furnished subsequently to this Authority for the purposes of search  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has be filed or furnished, the required statements that the information in the subsequent or additional copies is identical to the in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	ъ.	on paper		
filed or furnished, the required statements that the information in the subsequent or additional copies is identical to the in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	c.	contained in the international application as filed  filed together with the international application in electronic form		
3. Additional comments:	2. 🔀	In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.		
	3.	Additional comments:		